TNF-alpha inhibitors in Systemic Lupus Erythematosus. A case report and a systematic literature review.

Abstract

Joint involvement is a common manifestation of systemic lupus erythematosus (SLE) and is described as a non-erosive mild synovitis. However some SLE patients may present a more severe joint involvement requiring aggressive therapy. We describe the case of a SLE patient with a severe arthritis unresponsive to methotrexate, successfully treated with anti-TNF-alpha drug as induction therapy and we report the results of a systematic literature review on the use of TNF-alpha inhibitors in SLE.

• Authors: Marta Mosca, Chiara Tani, Maria Elena Filice, Linda Carli, Andrea Delle Sedie, Sabrina Vagnani, Alessandra Della Rossa, Chiara Baldini, Stefano Bombardieri
• Journal: Modern rheumatology (Mod Rheumatol) Vol. 25 Issue 4 Pg. 642-5 (Jul 2015) ISSN: 1439-7609 [Electronic] England
• PMID: 24252029 (Publication Type: Case Reports, Journal Article, Review, Systematic Review)

Chemical References

• Immunosuppressive Agents
• Tumor Necrosis Factor-alpha
• Certolizumab Pegol

Topics

• Adult
• Certolizumab Pegol (therapeutic use)
• Female
• Humans
• Immunosuppressive Agents (therapeutic use)
• Lupus Erythematosus, Systemic (drug therapy)
• Tumor Necrosis Factor-alpha (antagonists & inhibitors, metabolism)